Drugs / VT-1598
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04208321 | Sep 2020 → Dec 2021 | coccidioidomycosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-04-11 | Mycovia Pharmaceuticals Inc. | Results Study Published in Antimicrobial Agents and Chemotherapy Finds Antifungal Compound VT-1598 Developed by Mycovia Pharmaceuticals Demonstrates In Vitro and In Vivo Activity Against Deadly Candida Auris Fungus mycovia.com ↗
today announced that oral drug candidate VT-1598 has shown in vitro and in vivo activity against Candida auris, an emerging multi-drug resistant fungal pathogen that presents a serious global health threat. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-04-11 | Mycovia Pharmaceuticals Inc. | Study Published in Antimicrobial Agents and Chemotherapy Finds Antifungal Compound VT-1598 Developed by Mycovia Pharmaceuticals Demonstrates In Vitro and In Vivo Activity Against Deadly Candida Auris Fungus mycovia.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VT-1598 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04208321 ↗ |
| Modality | Small molecule | — CHEMBL4594426 ↗ |
| Route | Oral | “single oral doses of VT-1598” NCT04208321 ↗ |